Translating genome-wide association findings into new therapeutics for psychiatry

Genome-wide association studies (GWAS) in psychiatry, once they reach sufficient sample size and power, have been enormously successful. The Psychiatric Genomics Consortium (PGC) aims for mega-analyses with sample sizes that will grow to >1 million individuals in the next 5 years. This should lead to hundreds of new findings for common genetic variants across nine psychiatric disorders studied by the PGC. The new targets discovered by GWAS have the potential to restart largely stalled psychiatric drug development pipelines, and the translation of GWAS findings into the clinic is a key aim of the recently funded phase 3 of the PGC. This is not without considerable technical challenges. These approaches complement the other main aim of GWAS studies, risk prediction approaches for improving detection, differential diagnosis, and clinical trial design. This paper outlines the motivations, technical and analytical issues, and the plans for translating PGC phase 3 findings into new therapeutics.

[1]  Peter M Visscher,et al.  Prediction of individual genetic risk to disease from genome-wide association studies. , 2007, Genome research.

[2]  T Grant Belgard,et al.  Genome-wide, integrative analysis implicates microRNA dysregulation in autism spectrum disorder , 2016, Nature Neuroscience.

[3]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[4]  P. O’Donnell,et al.  Translating Human Genetics into Novel Treatment Targets for Schizophrenia , 2014, Neuron.

[5]  John Moult,et al.  GWAS and drug targets , 2014, BMC Genomics.

[6]  D. Wilkin,et al.  Neuron , 2001, Brain Research.

[7]  Hyejung Won,et al.  The road to precision psychiatry: translating genetics into disease mechanisms , 2016, Nature Neuroscience.

[8]  Joris M. Mooij,et al.  MAGMA: Generalized Gene-Set Analysis of GWAS Data , 2015, PLoS Comput. Biol..

[9]  Michael J. Purcaro,et al.  The PsychENCODE project , 2015, Nature Neuroscience.

[10]  Jake K. Byrnes,et al.  Genome-wide association study of copy number variation in 16,000 cases of eight common diseases and 3,000 shared controls , 2010 .

[11]  Simon C. Potter,et al.  Genome-wide Association Analysis Identifies 14 New Risk Loci for Schizophrenia , 2013, Nature Genetics.

[12]  C. Spencer,et al.  A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects: CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium , 2016, bioRxiv.

[13]  D. Pinto,et al.  Genome Wide Association Analysis of Copy Number Variation in Recurrent Depressive Disorder , 2011, Molecular Psychiatry.

[14]  Li Li,et al.  The benefits of using genetic information to design prevention trials. , 2013, American journal of human genetics.

[15]  D. Collier,et al.  Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia , 2016, Journal of psychopharmacology.

[16]  Kenji Mizuguchi,et al.  Systems Biology Approaches to a Rational Drug Discovery Paradigm. , 2015, Current topics in medicinal chemistry.

[17]  Y. Okada.  From the era of genome analysis to the era of genomic drug discovery: a pioneering example of rheumatoid arthritis , 2014, Clinical genetics.

[18]  Esben Agerbo,et al.  Polygenic Risk Score, Parental Socioeconomic Status, Family History of Psychiatric Disorders, and the Risk for Schizophrenia: A Danish Population-Based Study and Meta-analysis. , 2015, JAMA psychiatry.

[19]  P. O’Reilly,et al.  An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis , 2017, Biological Psychiatry.

[20]  T. Lehtimäki,et al.  Integrative approaches for large-scale transcriptome-wide association studies , 2015, Nature Genetics.

[21]  Jianxin Shi,et al.  Developing and evaluating polygenic risk prediction models for stratified disease prevention , 2016, Nature Reviews Genetics.

[22]  Eric S. Lander,et al.  A polygenic burden of rare disruptive mutations in schizophrenia , 2014, Nature.

[23]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[24]  Richard Barnett.  Diabetes , 1904, The Lancet.

[25]  Dan M. Roden,et al.  Implementing genomic medicine in the clinic: the future is here , 2013, Genetics in Medicine.

[26]  Mulin Jun Li,et al.  Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .

[27]  Laura J. Scott,et al.  Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways , 2015, Nature Neuroscience.

[28]  E. Shorter.  A Brief History of Placebos and Clinical Trials in Psychiatry , 2011, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[29]  Daniel S. Himmelstein,et al.  Understanding multicellular function and disease with human tissue-specific networks , 2015, Nature Genetics.

[30]  Giulio Genovese,et al.  Schizophrenia risk from complex variation of complement component 4 , 2016, Nature.

[31]  Peter B. Jones,et al.  Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General Population. , 2016, JAMA psychiatry.

[32]  A. Papassotiropoulos,et al.  Failed drug discovery in psychiatry: time for human genome-guided solutions , 2015, Trends in Cognitive Sciences.

[33]  J. O’Connell,et al.  Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels. , 2015, Human molecular genetics.

[34]  H. Fibiger.  Psychiatry, the pharmaceutical industry, and the road to better therapeutics. , 2012, Schizophrenia bulletin.

[35]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[36]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[37]  K. Mossman.  The Wellcome Trust Case Control Consortium, U.K. , 2008 .

[38]  E. Pearson.  Zinc transport and diabetes risk , 2014, Nature Genetics.

[39]  Benjamin A. Logsdon,et al.  Gene Expression Elucidates Functional Impact of Polygenic Risk for Schizophrenia , 2016, Nature Neuroscience.

[40]  Adam J. Schwarz,et al.  CNVs conferring risk of autism or schizophrenia affect cognition in controls , 2013, Nature.

[41]  Ryan S. Lee,et al.  Linking the SWI/SNF complex to prostate cancer , 2013, Nature Genetics.

[42]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[43]  Opportunities for New Drug Development in Psychiatry: A Glass Half-Full. , 2015, JAMA psychiatry.

[44]  Jianxin Shi,et al.  Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs , 2013, Nature Genetics.

[45]  D. Altshuler,et al.  Pathways Targeted by Antidiabetes Drugs Are Enriched for Multiple Genes Associated With Type 2 Diabetes Risk , 2014, Diabetes.

[46]  E. Banks,et al.  De novo mutations in schizophrenia implicate synaptic networks , 2014, Nature.

[47]  Kaanan P. Shah,et al.  A gene-based association method for mapping traits using reference transcriptome data , 2015, Nature Genetics.

[48]  JAMA Psychiatry. , 2018, JAMA psychiatry.

[49]  N. Brandon,et al.  Future Viable Models of Psychiatry Drug Discovery in Pharma , 2013, Journal of biomolecular screening.

[50]  M. Rieder,et al.  Combined Influence of LDLR and HMGCR Sequence Variation on Lipid-Lowering Response to Simvastatin , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[51]  B. Bettencourt,et al.  Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial , 2014, The Lancet.

[52]  Gerome Breen,et al.  Polygenic risk scores in imaging genetics: Usefulness and applications , 2015, Journal of psychopharmacology.